Lot consistency as an equivalence problem

Journal of Biopharmaceutical Statistics

Volumn 14, Issue 2, 2004, Pages 275-290

  Lachenbruch, P A ^a   Rida, W ^b   Kou, J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b University of Iowa   (United States)

Author keywords

Density estimation; Multiple group equivalence; Overlap

Indexed keywords

VACCINE;

ARTICLE; COMPUTER SIMULATION; DATA ANALYSIS; DENSITY; DENSITY ESTIMATION; DRUG APPROVAL; DRUG MANUFACTURE; DRUG QUALITY; EQUIVALENCE MARGIN; LOT CONSISTENCY; MULTIPLE GROUP EQUIVALENCE; NORMAL DISTRIBUTION; OVERLAP; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNITED STATES; VACCINE PRODUCTION;

MODELS, THEORETICAL; THERAPEUTIC EQUIVALENCY; VACCINES;

EID: 2642549807     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-120037179     Document Type: Article

References (17)

1. Chan, I. S. F., Li, S., Matthews, H., Chan, C., Vessey, R., Sadoff, J., Heyse, J. (2002). Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Statist. Med. 21:3411-3430.
2. Cheuvart, B., Bollaerts, A. (1999). Sample size considerations for assessing vaccine consistency through equivalence. Drug Inf. J. 33:149-151.
3. Cleveland, W., Lachenbruch, P. (1974). A measure of divergence among several populations. Commun. Statist. 33:201-211.
4. David, H. A., Lachenbruch, P. A., Brandis, H. P. (1972). The power function of range and studentized range in normal samples. Biometrika 59:161-168.
5. Giani, G., Finner, H. (1991). Some general results on least favorable parameter configurations with special reference to equivalence testing and the range statistic. J. Statist. Plann. Inference 28:33-47.
6. Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing, and Clinical Studies. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, April 1997.
7. Guidance for Industry Statistical Approaches to Establishing Bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, January 2001.
8. Moulton, L. H., Halsey, N. A. (1996). A mixed gamma model for regression analyses of quantitative assay data. Vaccine 14:1154-1158.
9. Ng, T. (2002) Iterative chi-square test for equivalence of multiple treatment groups. In: Proceedings of the Biopharmaceutical Section, Joint Statistical Meetings.
10. Poirier, M. K., Poland, G. A., Jacobson, R. M. (1996). Parameters potentially affecting interpretation of immunogenicity and efficacy data in vaccine trials: Are they adequately reported? Vaccine 14:25-27.
11. Rida, W. N. (2002) Assessing vaccine efficacy with correlates of immune protection: The surrogate endpoint problem. International Biometric Society (ENAR) Spring Meeting.
12. Schuirmann, D. (1987). A comparison of the two one-sided tests procedure and the power for assessing the equivalence of average bioavailability. J. Pharmacokinetics and Biopharmaceutics 15:657-680.
13. StataCorp. (2001) Stata Statistical Software: Release 7.0. College Station, TX: Stata Corporation. [Note, Release 8.0 was released in January 2003].
14. Stine, R., Heyse, J. (2001). Non-parametric estimates of overlap. Statist. Med. 20:215-236.
15. Wellek, S. (2003). Testing Statistical Hypotheses of Equivalence. Boca Raton, FL: Chapman and Hall/CRC.
16. Wiens, B. (1999). When log-normal and gamma models give different results: A case study. Amer. Statist. 53:89-93.
17. Wiens, B., Iglewicz, B. (1999). On testing equivalence of three populations. J. Biopharmaceutical Statist. 9:465-483.